Clincosm LogoSign in Get a demo

Mucin in Sputum of CF During Pulmonary Exacerbation

Sponsor
Philipps University Marburg Medical Center (Other)
Overall Status
Unknown status
CT.gov ID
NCT00202072
Collaborator
(none)
25
Enrollment
2
Locations
20
Duration (Months)
12.5
Patients Per Site
0.6
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to determine whether mucin is increased during pulmonay exacerbations in adult patients with cystic fibrosis (CF).

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    CF is typically associated with mucus hypersecretion in the airways. In health, mucin is the major macromolecular component and is responsible for the protective and clearance properties of the mucus gel. In a recent study we found that mucins are decreased in the sputum of adult CF patients.

    In this study we want to investigate the differences on the mucin and DNA quantity and quality of airway secretions in during pulmoanry exacerbation.We hypothesize that during an exacerbation the mucin and DNA amount is increasing.

    The aim of this study is to evaluate the molecular (mucins) and structure properties (mucin-DNA-network) of the airway secretions in CF related to the severity of the disease.

    We characterize sputum composition of patients with pulmonary exacerbations. Using gel electrophoresis and dot-blot with specific antibodies we will analyze MUC5AC and MUC5B mucins. DNA amount will be measured by microfluorimetry. With the laser scanning confocal microscopy the mucin-DNA-network will be evaluated.

    The significance of these studies is that they will give us novel information about the pathogenesis of chronic inflammatory airway diseases, provide tools for assessing the progression of lung disease, and most critically, will identify novel opportunities and targets for therapeutic intervention.

    Study Design

    Study Type:
    Observational
    Observational Model:
    Defined Population
    Time Perspective:
    Retrospective
    Study Start Date :
    Jan 1, 2004
    Study Completion Date :
    Sep 1, 2005

    Outcome Measures

    Primary Outcome Measures

      Eligibility Criteria

      Criteria

      Ages Eligible for Study:
      18 Years and Older
      Sexes Eligible for Study:
      All
      Accepts Healthy Volunteers:
      No
      Inclusion Criteria:

      • cystic fibrosis

      • chronic pseudomonas aeruginosa inflammation

      • pulmonary exacerbation

      Exclusion Criteria:

      Contacts and Locations

      Locations

      Site City State Country Postal Code
      1 Pediatric department, CF center, University Giessen Giessen Germany
      2 Pediatric department, CF center, University Marburg Marburg Germany

      Sponsors and Collaborators

      • Philipps University Marburg Medical Center

      Investigators

      • Principal Investigator: Markus O Henke, MD, Philipps University Marburg Medical Center

      Study Documents (Full-Text)

      None provided.

      More Information

      Publications

      Responsible Party:
      , ,
      ClinicalTrials.gov Identifier:
      NCT00202072
      Other Study ID Numbers:
      • 208/03
      First Posted:
      Sep 20, 2005
      Last Update Posted:
      Sep 20, 2005
      Last Verified:
      Sep 1, 2005
      Keywords provided by , ,
      lung
      airway
      pulmonary exacerbation
      mucus
      Additional relevant MeSH terms:
      Cystic Fibrosis

      Study Results

      No Results Posted as of Sep 20, 2005